Hansa Biopharma (Sweden) Today
| HNSA Stock | SEK 31.50 0.82 2.67% |
Performance0 of 100
| Odds Of DistressOver 54
|
Hansa Biopharma is selling for under 31.50 as of the 26th of November 2024; that is 2.67 percent increase since the beginning of the trading day. The stock's last reported lowest price was 30.52. Hansa Biopharma has 54 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. Equity ratings for Hansa Biopharma AB are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 27th of October 2024 and ending today, the 26th of November 2024. Click here to learn more.
Hansa Biopharma AB , a biopharmaceutical company, focuses on developing novel immunomodulatory enzymes for organ transplantation and autoimmune diseases. Hansa Biopharma AB was founded in 2001 and is headquartered in Lund, Sweden. Hansa Biopharma operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. The company has 52.44 M outstanding shares. More on Hansa Biopharma AB
Moving together with Hansa Stock
Moving against Hansa Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Hansa Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Hansa Biopharma's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Hansa Biopharma or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| President | Henk Troostwijk |
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Hansa Biopharma AB (HNSA) is traded on Stockholm Exchange in Sweden and employs 150 people. The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.82 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Hansa Biopharma's market, we take the total number of its shares issued and multiply it by Hansa Biopharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Hansa Biopharma AB operates under Healthcare sector and is part of Biotechnology industry. The entity has 52.44 M outstanding shares.
Hansa Biopharma AB has accumulated about 762.73 M in cash with (504.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 19.06.
Check Hansa Biopharma Probability Of Bankruptcy
Ownership AllocationHansa Biopharma AB has a total of 52.44 Million outstanding shares. 30% of Hansa Biopharma AB outstanding shares are owned by outside corporations. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Hansa Ownership Details
Hansa Biopharma AB Risk Profiles
Although Hansa Biopharma's alpha and beta are two of the key measurements used to evaluate Hansa Biopharma's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 2.48 | |||
| Standard Deviation | 3.49 | |||
| Variance | 12.16 | |||
| Risk Adjusted Performance | (0.13) |
Hansa Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Hansa Biopharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Fundamental Analysis Now
Fundamental AnalysisView fundamental data based on most recent published financial statements |
| All Next | Launch Module |
Hansa Biopharma Corporate Executives
Elected by the shareholders, the Hansa Biopharma's board of directors comprises two types of representatives: Hansa Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Hansa. The board's role is to monitor Hansa Biopharma's management team and ensure that shareholders' interests are well served. Hansa Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Hansa Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Donato Spota | CFO VP | Profile |
Additional Tools for Hansa Stock Analysis
When running Hansa Biopharma's price analysis, check to measure Hansa Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hansa Biopharma is operating at the current time. Most of Hansa Biopharma's value examination focuses on studying past and present price action to predict the probability of Hansa Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hansa Biopharma's price. Additionally, you may evaluate how the addition of Hansa Biopharma to your portfolios can decrease your overall portfolio volatility.